New oral anticoagulants in practice: Pharmacological and practical considerations

American Journal of Cardiovascular Drugs

Volumn 14, Issue 3, 2014, Pages 175-189

  Wang, Yishen ^a   Bajorek, Beata ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ADOLESCENCE; ADVERSE DRUG REACTION; AGING; ALTERNATIVE MEDICINE; ANTICOAGULANT THERAPY; BLOOD CLOTTING PARAMETERS; CLINICAL PRACTICE; CREATININE CLEARANCE; DIET SUPPLEMENTATION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL DISEASE; GENDER; HEALTH PRACTITIONER; HERB; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LACTATION; LIVER DYSFUNCTION; MEDICATION COMPLIANCE; PARTIAL THROMBOPLASTIN TIME; PEDIATRICS; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOGENOMICS; PHARMACOKINETICS; POLYPHARMACY; PREGNANCY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; ANALOGS AND DERIVATIVES; COMPLICATION; DRUG INTERACTION; HEART ATRIUM FIBRILLATION; KIDNEY DISEASES; LIVER DISEASES; ORAL DRUG ADMINISTRATION; SEX DIFFERENCE; STROKE;

ADMINISTRATION, ORAL; AGING; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COMPLEMENTARY THERAPIES; DRUG INTERACTIONS; DRUG MONITORING; HUMANS; INTERNATIONAL NORMALIZED RATIO; KIDNEY DISEASES; LIVER DISEASES; MORPHOLINES; PYRAZOLES; PYRIDONES; SEX FACTORS; STROKE; THIOPHENES; WARFARIN;

EID: 84904260419     PISSN: 11753277     EISSN: 1179187X     Source Type: Journal    
DOI: 10.1007/s40256-013-0061-0     Document Type: Review

References (82)

1. Bajorek BV, Ogle SJ, Duguid MJ, Shenfield GM, Krass I, Bajorek BV, et al. Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers. Med J Aust. 2007;186:175-80. (Pubitemid 46380865)
2. Bristol-Myers Squibb Company. Coumadin (warfarin sodium) highlights of prescribing information. 2011. http://packageinsertsbmscom/pi/pi-coumadinpdf. Accessed 11 April 2013.
3. Australian government Department of Health and Ageing. Review of anticoagulation therapies in atrial fibrillation. 2012. http://wwwpbsgovau/ reviews/atrial-fibrillation-files/issues-and-options-paperpdf. Accessed 29 April 2013.
4. Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation clinical perspective. Circulation. 2011;123:2562-70.
5. Aspen Pharma. Coumadin (warfarin sodium) product information. 2010. http://wwwaspenpharmacomau/product-info/pi/PI- Coumadinpdf. Accessed 11 April 2013.
6. Bayer Australia. Xarelto (rivaroxaban) product information. 2012. http://wwwbayerresourcescomau/resources/uploads/PI/file9466pdf. Accessed 11 April 2013.
7. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost. 2009;15(Suppl 1):9S-16S.
8. Boeringer Ingelheim. Pradaxa (dabigatran etexilate) product information. 2012. http://wwwpbsgovau/reviews/atrial-fibrillation-files/14a-boehringer- ingelheim-appendicespublicpdf. Accessed 11 April 2013.
9. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf. 2006;5:433-51.
10. Bristol-Myers Squibb. Eliquis (apixaban) product information. 2012. http://securehealthlinksnetau/content/bms/picfm?product=bqpeliqu11112. Accessed 11 April 2013.
11. Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man. Eur J Clin Pharmacol. 1987;32:165-72. (Pubitemid 17053292)
12. Beatty SJ, Mehta BH, Rodis JL. Decreased warfarin effect after initiation of high-protein, low-carbohydrate diets. Ann Pharmacother. 2005;39:744-7. (Pubitemid 40396633)
13. Fagan TC, Oexmann MJ. Effects of high protein, high carbohydrate, and high fat diets on laboratory parameters. J Am Coll Nutr. 1987;6:333-43.
14. Dang M-TN, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39:1008-12. (Pubitemid 40695964)
15. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM. Warfarin maintenance dosing patterns in clinical practice implications for safer anticoagulation in the elderly population. Chest. 2005;127:2049-56.
16. Teles JS, Fukuda EY, Feder D. Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein (Sao Paulo). 2012;10:110-5.
17. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386-99. (Pubitemid 351185753)
18. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285-95. (Pubitemid 351508116)
19. Nutescu EA. Oral anticoagulant therapies: balancing the risks. Am J Health Syst Pharm. 2013;70(Suppl 1):S3-11.
20. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47-59. (Pubitemid 350260888)
21. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100:453-61.
22. Buller HR, Lensing AW, Prins MH, Agnelli G, Cohen A, Gallus AS, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood. 2008;112:2242-7.
23. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-80. (Pubitemid 41803696)
24. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-91.
25. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86. (Pubitemid 351930852)
26. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-80.
27. Douketis JD. Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des. 2010;16:3436-41.
28. Moyer TP, O'Kane DJ, Baudhuin LM, Wiley CL, Fortini A, Fisher PK, et al. Warfarin sensitivity genotyping: a review of the literature and summary of patient experience. Mayo Clin Proc. 2009;84:1079-94.
29. Pare G, Eriksson N, Lehr T, Connolly S, Eikelboom J, Ezekowitz MD, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding. Circulation. 2013;127:1404-12.
30. Bristol-Myers Squibb. Eliquis (apixaban) prescription information. 2012. http://wwwaccessdatafdagov/drugsatfda-docs/label/2012/202155s000lblpdf. Accessed 11 April 2013.
31. Pharmaceuticals J. Xarelto (rivaroxaban) highlights of prescribing information. 2011. http://wwwaccessdatafdagov/drugsatfda-docs/label/2011/ 202439s001lblpdf. Accessed 11 April 2013.
32. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement - a systematic review and meta analysis. Thromb Res. 2010;125:e159-66.
33. Gulseth MP, Grice GR, Dager WE. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm. 2009;66:123-33.
34. Monagle P, Chalmers E, Chan A, Kirkham F, Massicotte P, Michelson AD. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133(6 Suppl):887S-968S. (Pubitemid 351892979)
35. Bristol-Myers Squibb Company. Highlights of prescribing information, Coumadin. 2011. http://wwwaccessdatafdagov/drugsatfda-docs/label/2011/ 009218s107lblpdf. Accessed 29 Nov 2013.
36. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e691S-736S.
37. Huq FY, Tvarkova K, Arafa A, Kadir RA. Menstrual problems and contraception in women of reproductive age receiving oral anticoagulation. Contraception. 2011;84:128-32.
38. Peake LJ, Grover SR, Monagle PT, Kennedy AD. Effect of warfarin on menstruation and menstrual management of the adolescent on warfarin. J Paediatr Child Health. 2011;47:893-7.
39. Jacobs LG. Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clin Geriatr Med. 2006;22:17-32. (Pubitemid 41827956)
40. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326-43.
41. Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e152S.
42. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol. 2002;54:349-56. (Pubitemid 35334946)
43. Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci. 2001;4:176-84. (Pubitemid 34305609)
44. Duthie GG, Kyle JA, Jenkinson AM, Duthie SJ, Baxter GJ, Paterson JR. Increased salicylate concentrations in urine of human volunteers after consumption of cranberry juice. J Agric Food Chem. 2005;53:2897-900. (Pubitemid 40525249)
45. Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther. 2006;79:125-33. (Pubitemid 43071237)
46. Buckley MS, Goff AD, Knapp WE. Fish oil interaction with warfarin. Ann Pharmacother. 2004;38:50-2.
47. Daugherty NE, Smith KM. Dietary supplement and selected food interactions with warfarin. Pharmacol Update. 2006;29:309-14.
48. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012;110:453-60.
49. Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ET. New oral anticoagulants increase the risk of gastrointestinal bleeding - a systematic review and meta-analysis. Ned Tijdschr Geneeskd. 2013;1(45):105-12.
50. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-51.
51. Bytzer P, Connolly SJ, Yang S, Ezekowitz M, Formella S, Reilly PA, et al. Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol. 2013;11(246-52):e1-5.
52. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke. JAMA. 2001;285:2864-70.
53. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-72.
54. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J. 2006;151:713-9. (Pubitemid 43290267)
55. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100.
56. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360-420.
57. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-226S.
58. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JI, Heit JA, et al. Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e227S-77S.
59. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S-325S.
60. Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e419S-94S.
61. Kuijer PMM, Hutten BA, Prins MH, Buller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med. 1999;159:457.
62. Ruíz-Giménez N, Suárez C, González R, Nieto JA, Todolí JA, Samperiz AL, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100:26-31. (Pubitemid 351952971)
63. Harenberg J, Giese C, Marx S, Kramer R. Determination of dabigatran in human plasma samples. Semin Thromb Hemost. 2012;38:16-22.
64. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116-27.
65. Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013. [Epub ahead of print].
66. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23:138-43.
67. Gouin-Thibault I, Flaujac C, Delavenne X, Quenet S, Horellou MH, Laporte S et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2013;111. [Epub ahead of print].
68. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev. 2012;3. doi:10.1002/14651858.
69. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-88S.
70. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016-23.
71. UW Medicine. Spontaneous intraparenchymal hemorrhage reversal guide for target specific oral anticoagulants. http://deptswashingtonedu/anticoag/home/ sites/default/files/IPH-DabigatranRivaroxabanApixaban- reversal-0pdf. Accessed 6 Aug 2013.
72. Brent Reed AM. UNC health care guideline management of dabigatran in adults. 2011. http://emcritorg/wp-content/uploads/dabigatran-unc-guideline3pdf. Accessed 28 Aug 2013.
73. Douketis JD, Spyropoulos AC, Spencer FA, Mayr M, Jaffer AK, Eckman MH, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e326S-50S.
74. Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Blood. 2012;120:4699-705.
75. Vílchez JA, Gallego P, Lip GY. Safety of new oral anticoagulant drugs: a perspective. Ther Adv Drug Saf. 2013;. doi:10.1177/2042098613507945.
76. Pototski M, Amenabar JM. Dental management of patients receiving anticoagulation or antiplatelet treatment. J Oral Sci. 2007;49:253-8.
77. Alaali Y, Barnes GD, Froehlich JB, Kaatz S. Management of oral anticoagulation in patients undergoing minor dental procedures. J Mich Dent Assoc. 2012;94:36-41.
78. Cushman M, Lim W, Zakai NA. 2011 clinical practice guide on anticoagulant dosing and management of anticoagulant-associated bleeding complications in adults. 2011. http://wwwhematologyorg/Practice/Guidelines/2934aspx. Accessed 17 July 2013.
79. Food and Drug Administration (FDA). FDA pregnancy categories. 2008. http://wwwgpogov/fdsys/pkg/FR-2008-05-29/pdf/E8-11806pdf. Accessed 18 Dec 2013.
80. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52.
81. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.
82. Mega JL, Braunwald E, Murphy SA, Plotnikov AN, Burton P, Kiss RG, et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51). J Am Coll Cardiol. 2013;61:1853-9.